Koers Respirerx Pharmaceuticals Inc Other OTC
Aandelen
US2205243007
Biotechnologie & Medisch Onderzoek
slotkoers
Andere beurzen
|
||
- USD | - |
Omzet 2021 | - | Omzet 2022 | - | Marktkapitalisatie | 289K 266K |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -3 mln. -2,76 mln. | Nettowinst (verlies) 2022 | -2 mln. -1,84 mln. | EV/omzet 2021 | - |
Nettoschuld 2021 | 2,08 mln. 1,91 mln. | Nettoschuld 2022 | 2,71 mln. 2,49 mln. | EV/omzet 2022 | - |
K/w-verhouding 2021 |
-0,29
x | K/w-verhouding 2022 |
-0,06
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 93,37% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Arnold Lippa
CEO | Chief Executive Officer | 77 | 22-03-13 |
Jeff Margolis
DFI | Director of Finance/CFO | 68 | 22-03-13 |
Richard Purcell
CTO | Chief Tech/Sci/R&D Officer | 63 | 15-10-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Arnold Lippa
CEO | Chief Executive Officer | 77 | 22-03-13 |
Director/Board Member | - | 22-03-23 | |
Jeff Margolis
DFI | Director of Finance/CFO | 68 | 22-03-13 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+9,42% | 115 mld. | |
+11,84% | 106 mld. | |
-1,05% | 21,96 mld. | |
-14,15% | 21,84 mld. | |
-5,29% | 19,21 mld. | |
-4,16% | 18,08 mld. | |
-38,29% | 17,71 mld. | |
+7,99% | 14,32 mld. | |
+36,24% | 12,42 mld. |
- Beurs
- Aandelen
- Koers RSPI
- Koers